Study #2017-0328
A Randomized, Double-blind, Placebo-Controlled Study of 4- hydroxytamoxifen Topical Gel in Women with Mammographically Dense Breast
MD Anderson Study Status
Not Accepting
Treatment Agent
Afimoxifene
Description
This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mammographically Dense Breast
Study phase:
Phase II
Physician name:
Banu Arun
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-563-0193
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.